Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer

  • Authors:
    • Su‑Juan Yuan
    • Tian‑Kui Qiao
    • Jin‑Wei Qiang
    • Song‑Qi Cai
  • View Affiliations

  • Published online on: April 17, 2019     https://doi.org/10.3892/or.2019.7124
  • Pages: 3335-3346
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dynamic contrast enhanced‑magnetic resonance imaging (DCE‑MRI) contributes to the early detection and prediction of responses to chemotherapy in cancer. The aim of the present study was to investigate the feasibility of quantitative DCE‑MRI parameters for noninvasively predicting the early response to DTX in epithelial ovarian cancer (EOC). In the present study, using 7,12‑dimethylbenz (A) anthracene, orthotopic EOC was induced in Sprague Dawley rats. Rats with EOC were treated with docetaxel (DTX) on day 0. DCE‑MRI was applied on days 0, 3, 7, 14 and 21. On day 21, the treated tumor types were categorized into sensitive and insensitive groups according to their change in size. Quantitative DCE‑MRI parameters were used to assess the early response to therapy. The experiment was performed again, the treatment group was divided into sensitive and insensitive groups according to their initially obtained cut-off values, and histopathological analyses were performed. Comparing the sensitive group with the insensitive group, there were significant differences in the percentage change in the volume transfer constant (Ktrans), rate constant (kep) and initial area under the curve (IAUC) from day 3 and tumor size from day 14. During the early stages of treatment (on day 3), the percentage change of Ktrans combined with kep produced an AUC of 1, and a sensitivity and specificity of 100 and 100%, respectively, using a cut-off value of a 17.59% reduction in Ktrans and kep. From day 7, there were significant differences in the quantitative index percentage change in angiogenesis in the sensitive group compared with the insensitive group. The percentage change in Ktrans, kep and IAUC were positively correlated with the percentage of change in tumor size and angiogenesis, and negatively correlated with the percentage of change in necrosis. The results of the present study indicated that quantitative DCE‑MRI parameters were superior to imaging tumor size for the early detection and prediction of the response to DTX chemotherapy in EOC.

References

1 

Pan Z and Xie X: BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget. 8:97657–97670. 2017.PubMed/NCBI

2 

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al: Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI

3 

Chen ZK, Cai MX, Yang J, Lin LW, Xue ES, Huang J, Wei HF, Zhang XJ and Ke LM: Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft. Med Oncol. 29:62–69. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Razi Soofiyani S, Mohammad Hoseini A, Mohammadi A, Khaze Shahgoli V, Baradaran B and Hejazi MS: siRNA-mediated silencing of CIP2A enhances docetaxel activity against PC-3 prostate cancer cells. Adv Pharm Bull. 7:637–643. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Liu P, Feng J, Sun M, Yuan W, Xiao R, Xiong J, Huang X, Xiong M, Chen W, Yu X, et al: Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells. Int J Oncol. 51:1878–1886. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, et al: HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. Int J Oncol. 53:99–112. 2018.PubMed/NCBI

7 

Armstrong SR, Narendrula R, Guo B, Parissenti AM, McCallum KL, Cull S and Lannér C: Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res. 5:402012. View Article : Google Scholar : PubMed/NCBI

8 

Cohen JG, White M, Cruz A and Farias-Eisner R: In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem. 5:286–300. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, et al: Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 22:1451–1464. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Padhani AR and Miles KA: Multiparametric imaging of tumor response to therapy. Radiology. 25:348–364. 2010. View Article : Google Scholar

12 

Yuh WT, Mayr NA, Jarjoura D, Wu D, Grecula JC, Lo SS, Edwards SM, Magnotta VA, Sammet S, Zhang H, et al: Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol. 44:343–350. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren S and Gribbestad IS: Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS. NMR Biomed. 23:56–65. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Tudorica A, Oh KY, Chui SY, Roy N, Troxell ML, Naik A, Kemmer KA, Chen Y, Holtorf ML, Afzal A, et al: Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI. Transl Oncol. 9:8–17. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Cebulla J, Huuse EM, Pettersen K, van der Veen A, Kim E, Andersen S, Prestvik WS, Bofin AM, Pathak AP, Bjørkøy G, et al: MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer. 112:504–513. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Lis E, Saha A, Peck KK, Zatcky J, Zelefsky MJ, Yamada Y, Holodny AI, Bilsky MH and Karimi S: Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy. Neurosurg Focus. 42:E92017. View Article : Google Scholar : PubMed/NCBI

17 

Yuan SJ, Qiao TK, Qiang JW, Cai SQ and Li RK: The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas. J Ovarian Res. 10:652017. View Article : Google Scholar : PubMed/NCBI

18 

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging. 10:223–232. 1999. View Article : Google Scholar : PubMed/NCBI

19 

Zhang P, Chen L, Zhang Z, Lin L and Li Y: Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol. 10:7541–7544. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, et al: Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 96:487–488. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Zhou LN, Wu N, Liang Y, Gao K, Li XY and Zhang LF: Monitoring response to gefitinib in nude mouse tumor xenografts by 18F-FDG microPET-CT: Correlation between 18F-FDG uptake and pathological response. World J Surg Oncol. 13:1112015. View Article : Google Scholar : PubMed/NCBI

22 

Kovač JD, Terzić M, Mirković M, Banko B, Đikić-Rom A and Maksimović R: Endometrioid adenocarcinoma of the ovary: MRI findings with emphasis on diffusion-weighted imaging for the differentiation of ovarian tumors. Acta Radiol. 57:758–766. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Khatun Z, Nurunnabi, Cho KJ, Byun Y, Bae YH and Lee YK: Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J Control Release. 177:64–73. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Whisenant JG, Sorace AG, McIntyre JO, Kang H, Sánchez V, Loveless ME and Yankeelov TE: Evaluating treatment responseusing DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts. Transl Oncol. 7:768–779. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

26 

de Bazelaire C, Siauve N, Fournier L, Frouin F, Robert P, Clement O, de Kerviler E and Cuenod CA: Comprehensive model for simultaneous MRI determination of perfusion and permeability using a blood-pool agent in rats rhabdomyosarcoma. Eur Radiol. 15:2497–2505. 2005. View Article : Google Scholar : PubMed/NCBI

27 

Boult JKR, Box G, Vinci M, Perryman L, Eccles SA, Jones C and Robinson SP: Evaluation of the response of intracranial xenografts to VEGF signaling inhibition using multiparametric MRI. Neoplasia. 19:684–694. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, et al: Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: Results of a prospective DCE-MRI study. Eur Radiol. 26:1404–11. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Ma L, Xu X, Zhang M, Zheng S, Zhang B, Zhang W and Wang P: Dynamic contrast-enhanced MRI of gastric cancer: Correlations of the pharmacokinetic parameters with histological type, Lauren classification, and angiogenesis. Magn Reson Imaging. 37:27–32. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D, et al: Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer. 130:2359–2365. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Yang J, Kim JH, Im GH, Heo H, Yoon S, Lee J, Lee JH and Jeon P: Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI. Korean J Radiol. 12:602–610. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Li L, Wang K, Sun X, Wang K, Sun Y, Zhang G and Shen B: Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer. Med Sci Monit. 21:376–382. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Yao WW, Zhang H, Ding B, Fu T, Jia H, Pang L, Song L, Xu W, Song Q, Chen K, et al: Rectal cancer: 3D dynamic contrast-enhanced MRI; correlation with microvascular density and clinicopathological features. Radiol Med. 116:366–374. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI

35 

Mikalsen LT, Dhakal HP, Bruland OS, Nesland JM and Olsen DR: Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections. Anticancer Res. 31:4053–4060. 2011.PubMed/NCBI

36 

Bando H: Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer. 14:163–173. 2007. View Article : Google Scholar : PubMed/NCBI

37 

Hayes DF, Miller K and Sledge G: Angiogenesis as targeted breast cancer therapy. Breast. 16 (Suppl 2):S17–S19. 2007. View Article : Google Scholar : PubMed/NCBI

38 

Ji Y, Hayashi K, Amoh Y, Tsuji K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M and Hoffman RM: The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res. 27:713–718. 2007.PubMed/NCBI

39 

Zhang Q, Kang X and Zhao W: Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun. 342:824–828. 2006. View Article : Google Scholar : PubMed/NCBI

40 

Zhang M, Tao W, Pan S, Sun X and Jiang H: Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs. 20:355–363. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Chen J, Qian T, Zhang H, Wei C, Meng F and Yin H: Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model. Magn Reson Imaging. 34:177–182. 2016. View Article : Google Scholar : PubMed/NCBI

42 

Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW, Chen YF, Chen JJ, Chen JH, Yang PC, et al: Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One. 6:e160622011. View Article : Google Scholar : PubMed/NCBI

43 

Wu L, Lv P, Zhang H, Fu C, Yao X, Wang C, Zeng M, Li Y and Wang X: Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model. Magn Reson Imaging. 33:737–760. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yuan, S., Qiao, T., Qiang, J., & Cai, S. (2019). Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer. Oncology Reports, 41, 3335-3346. https://doi.org/10.3892/or.2019.7124
MLA
Yuan, S., Qiao, T., Qiang, J., Cai, S."Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer". Oncology Reports 41.6 (2019): 3335-3346.
Chicago
Yuan, S., Qiao, T., Qiang, J., Cai, S."Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer". Oncology Reports 41, no. 6 (2019): 3335-3346. https://doi.org/10.3892/or.2019.7124